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Myc-mediated repression of microRNA-34a promotes high grade
transformation of B-cell lymphoma by dysregulation of FoxP1
Abstract
Gastric marginal zone B-cell lymphoma of MALT type (MALT lymphoma) arises in the context of
chronic inflammation induced by the bacterial pathogen Helicobacter pylori. Although generally
considered an indolent disease, MALT lymphoma may transform to gastric diffuse large B-cell
lymphoma (gDLBCL) through mechanisms that remain poorly understood. By comparing microRNA
expression profiles of gastric MALT lymphoma and gDLBCL, we have identified a signature of 27
deregulated microRNAs (miRNAs) that share the characteristic of being transcriptionally repressed by
Myc. Myc over-expression was consequently detected in 80% of gDLBCL, but only 20% of MALT
lymphomas spotted on a tissue microarray. A highly similar signature of Myc-repressed miRNAs was
further detected in nodal DLBCL. The siRNA-mediated knock-down of Myc blocked proliferation of
DLBCL cell lines. Of the Myc-repressed miRNAs downregulated in malignant lymphoma, miR-34a
showed the strongest anti-proliferative properties when overexpressed in DLBCL cells. We could
further attribute miR-34a's tumor suppressive effects to deregulation of its target FoxP1. FoxP1
over-expression was detected in gDLBCL, but not in gastric MALT lymphoma; FoxP1 knock-down
efficiently blocked DLBCL proliferation. In conclusion, our results elucidate a novel Myc- and
FoxP1-dependent pathway of malignant transformation and suggest miR-34a replacement therapy as a
promising strategy in lymphoma treatment.
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ABSTRACT 
Gastric marginal zone B-cell lymphoma of MALT type (MALT lymphoma) arises in the 
context of chronic inflammation induced by the bacterial pathogen Helicobacter pylori. 
Although generally considered an indolent disease, MALT lymphoma may transform to 
gastric diffuse large B-cell lymphoma (gDLBCL) through mechanisms that remain poorly 
understood. By comparing microRNA expression profiles of gastric MALT lymphoma and 
gDLBCL, we have identified a signature of 27 deregulated microRNAs (miRNAs) that share 
the characteristic of being transcriptionally repressed by Myc. Myc over-expression was 
consequently detected in 80% of gDLBCL, but only 20% of MALT lymphomas spotted on a 
tissue microarray. A highly similar signature of Myc-repressed miRNAs was further detected 
in nodal DLBCL. The siRNA-mediated knock-down of Myc blocked proliferation of DLBCL 
cell lines. Of the Myc-repressed miRNAs downregulated in malignant lymphoma, miR-34a 
showed the strongest anti-proliferative properties when overexpressed in DLBCL cells. We 
could further attribute miR-34a’s tumor suppressive effects to deregulation of its target 
FoxP1. FoxP1 over-expression was detected in gDLBCL, but not in gastric MALT 
lymphoma; FoxP1 knock-down efficiently blocked DLBCL proliferation. In conclusion, our 
results elucidate a novel Myc- and FoxP1-dependent pathway of malignant transformation 
and suggest miR-34a replacement therapy as a promising strategy in lymphoma treatment.  
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INTRODUCTION 
Gastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type 
is a “low grade” extranodal B-cell lymphoma that arises in the context of chronic gastric 
inflammation induced by persistent Helicobacter pylori infection.1 In its early stages, MALT 
lymphoma is an indolent and localized disease that can be treated by antibiotic eradication 
therapy targeting the underlying infection.2 In line with the concept that gastric MALT 
lymphomas are antigen-driven tumors, the surface immunoglobulins of MALT lymphoma B-
cells are clonal, somatically hypermutated, and have undergone positive selection.3 We have 
shown recently that MALT lymphoma tumor immunoglobulins (Igs) are polyreactive, i.e. 
they bind with similar affinity to various unrelated self and foreign antigens, and show a 
biased use of Ig VH gene segments previously linked to poly- and autoreactive antibodies.4 
Early MALT lymphomas further require T-cell help in the form of soluble T-helper cell-
derived signals, most likely B-cell mitogenic cytokines such as IL-4 and IL-5.5  
Low grade MALT lymphomas may progress to more aggressive disease, either through the 
acquisition of one of three characteristic chromosomal translocations resulting in the 
constitutive activation of the NF-κB signaling pathway,2 or through the histologically evident 
transformation to “high grade” gastric diffuse large B-cell lymphoma (gDLBCL).6,7 High 
grade transformation of Helicobacter-associated MALT lymphoma accounts for the majority 
of gDLBCL cases, whereas primary gDLBCL is rare.6,7 gDLBCL is characterized by antigen-
independent growth, resistance to Helicobacter eradication therapy and a number of genetic 
alterations that may contribute to high grade transformation.8 In particular, TP53 mutations,9  
Bcl6 overexpression10 and the aberrant DNA hypermethylation of tumor suppressor genes11 
have been shown to be associated with high grade transformation. However, the precise 
molecular mechanisms underlying the transition from low grade MALT lymphoma to 
gDLBCL remain largely unclear.  
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MicroRNAs (miRNAs) are an abundant class of small non-coding RNAs that modulate the 
expression of their target genes at the post-transcriptional level. Aberrant expression of 
specific miRNAs has been associated with both solid organ and hematopoietic 
malignancies,12 including chronic lymphocytic leukemia,13 lung cancer14,15 and ovarian 
cancer.16,17 The majority of human miRNAs are located at fragile sites or cancer associated 
genomic regions.17 For example, the frequent downregulation of the fragile region encoding 
miR-15a and miR-16-1 promotes chronic lymphocytic leukemia through deregulation of the 
Bcl2 oncogene.13 The widespread deregulation of the miRNA transcriptome appears to be a 
hallmark of cancer and has been attributed to deletions, amplifications or mutations of 
miRNA loci,16,17 epigenetic silencing,18 or the aberrant transcriptional regulation of miRNA 
genes.16 Several studies have revealed the potential of miRNA expression profiles as 
diagnostic and prognostic markers of cancers,15 which may be more useful than expression 
analysis of protein-coding genes for the classification and stratification of cancer subtypes.12  
Here, we have used a microarray approach to identify miRNAs that are differentially 
regulated in gastric low grade MALT lymphoma and its transformed high grade disease 
counterpart. Interestingly, we found that a characteristic set of Myc-repressed miRNAs was 
downregulated in the high grade, but not the low grade cases studied. Aberrant Myc 
expression indeed correlated with high grade transformation as analyzed 
immunohistochemically using a gastric lymphoma tissue microarray. Bioinformatic target 
prediction combined with functional analyses revealed that one of the miRNAs found to be 
downregulated in high grade gDLBLC, miR-34a, represents a bona fide tumor suppressor 
miRNA in DLBCL. miR-34a acts through post-transcriptional control of its direct target 
FoxP1, a hematopoietic oncoprotein overexpressed in gDLBCL. In conclusion, our findings 
identify a new mechanism that links the aberrant expression of Myc and the resulting 
repression of the tumor suppressor miRNA miR-34a to FoxP1 deregulation in high grade 
transformation of gastric B-cell lymphoma. 
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MATERIALS AND METHODS  
 
Patient material and lymphoma cell lines 
For miRNA expression analysis of archived patient material, consecutive cases of H. pylori-
positive gastritis, H. pylori-positive gastric low grade MALT lymphoma, and gDLBCL were 
drawn from the surgical pathology files of the Institute of Pathology at the Cantonal Hospital 
St. Gallen and from the files of the Institute for Surgical Pathology, University Hospital 
Zürich, Switzerland. Diagnosis was performed according to the WHO-classification system 
on formalin fixed, paraffin embedded tissue. All data were blinded to guarantee patients' 
protection. All procedures were in agreement with the guidelines for use of human material in 
research issued by the Ethics Committees of the Cantonal Hospital St. Gallen and the Canton 
of Zurich. The DLBCL and marginal zone lymphoma cell lines used were SUDHL4 and 
SUDHL6 (both DLBCL of ‘GCB’ type), U2932 (DLBCL, ‘ABC’ type), SUDHL7 (DLBCL, 
unclassified) and SSK41 (marginal zone lymphoma). All cell lines were maintained at 37 °C 
in RPMI 1640 medium supplemented with 20% heat-inactivated fetal bovine serum and 
antibiotics. 
 
RNA extraction, microRNA expression profiling by microarray analysis and locked 
nucleic acid real time PCR for microRNA quantification 
Total RNA was extracted from three 20 μm slices per sample of formalin fixed, paraffin 
embedded material using the RecoverAll total RNA Isolation kit (Ambion, Streetsville, 
Canada). Total RNA concentrations were measured using an ND-1000 spectrophotometer 
(NanoDrop Technologies). RNA integrity was confirmed on an Agilent 2100 Bioanalyzer 
(Agilent Technologies, Santa Clara, CA, USA). All microarray experiments were performed 
using the Agilent Human miRNA Microarray Kit version 10.0. 100 ng total RNA were 
hybridized per sample and processed according to the manufacturer’s instructions. The arrays 
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were scanned with an Agilent Technology G2565B scanner. The scanned images were 
gridded and analyzed using Agilent Feature Extraction Software version 9.5. The 795 human 
mature miRNAs included on the array were represented by 2421 probes; the average intensity 
of all probes corresponding to one miRNA was calculated. Normalization was performed 
using quantile normalization implemented in the bioconductor package PreprocessCore. The 
false discovery rate was computed using the Benjamini-Hochberg algorithm. All raw data of 
the microarray experiments are publicly accessible under the accession number GSE24485 
(http://www.ncbi.nlm.nih.gov/geo/). The expression of mature miRNAs was analysed using 
the miRCURY locked nucleic acid (LNA) microRNA PCR system following the 
manufacturer’s instructions (Exiqon, Vedbaek, Denmark). Briefly, 10 ng of total RNA was 
subjected to cDNA synthesis using either miRNA- or U6 snRNA-specific primers. The cDNA 
template was diluted 1:10 and real time PCR reactions were performed following the 
manufactures’ recommendations (LightCycler; Roche, Basel, CH). Calculations of miRNA 
expression levels were performed using the comparative ΔΔCt method and normalized against 
U6 snRNA levels. 
 
Small RNA cloning, sequence annotation and differential expression detection 
Small RNA cloning was carried out by Vertis Biotechnology (Weihenstephan, Germany) as 
described.19 The small RNA fraction from four cases each of nodal DLBCL and follicular 
lymphoma was isolated using the miRVana-microRNA isolation kit (Ambion, Austin, USA), 
run on 12.5 % polyacrylvamide gel and stained with SYBR greenII. The 15-40 nt fraction was 
eluted and poly-adenylated using poly(A) polymerase, and an adaptor was ligated to the 5’-
phosphate of the miRNAs (5’-end adaptor, 43 nucleotides:  5’-GCCTCCCTCGCGCCATC 
AGCTNNNNGACCTTGGCTGTCACTCA-3’; NNNN represents a barcode sequence). First 
strand cDNA synthesis was performed using an oligo(dT)- linker primer and M-MLV-
RNaseH reverse transcriptase (3’-end oligo dT linker primer: 5’-GCCTTGCCAGCC 
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CGCTCAGACGAGACATCGCCCCG C(T)25-3’). The resulting cDNAs were amplified in 
22 cycles using the high-fidelity Phusion polymerase (Finnzymes, Espoo, Finland). The 
resulting 120–135bp amplification products were electro-eluted from 6% PAA gels. After 
isolation with Nucleospin Extract II (Macherey and Nagel, Bethlehem, USA), the cDNA was 
dissolved in 5 mM Tris/HCl (pH 8.5) at a concentration of 10 ng/ml and used in single-
molecule sequencing. Massively parallel sequencing was performed by 454 Life Sciences 
(Branford, USA) using the Genome Sequencer 20 system. Sequence analysis and small RNA 
derived library annotation was done semi-manually as described.19 Relative miRNA 
abundance in indolent nodal lymphoma and nodal DLBCL was compared based on the 
miRNA reads normalized to the total number of annotated miRNAs.  
 
Immunohistochemical staining, Western blotting and fluorescence in situ hybridization 
The gastric lymphoma tissue microarray used in this study was previously described20 and 
included a total of 76 specimens, comprising 39 cases of gastric low grade MALT lymphomas 
and 37 cases of gDLBCL. The following primary antibodies were used: anti-Myc (N-262; 
Santa Cruz Biotechnology), anti-FoxP1 (ICI2; Abcam), anti-p53 (M7001; Dako) and anti-
p21/WAF (NCL-WAF-1; Novocastra). Myc and FoxP1 levels were assessed by counting the 
number of positively staining tumor cells and graded using the following expression scale: a 
negligible level of staining of 0-10% was recorded as negative, while low expression was 
between 10-60% and high expression was recorded when 60-100% tumor cells stained 
positive. Protein extracts from cell lines were made in 2x Laemmli sample buffer (4% SDS, 
20% glycerol, 120mM Tris [pH6.8]). Proteins were separated by SDS/polyacrylamide gel 
electrophoresis and transferred onto nitrocellulose membranes. Membranes were probed with 
antibodies against FoxP1 (JC12; Abcam) or against α-tubulin (Santa Cruz Biotechnology) to 
control for equivalent gel loading. The MYC gene status was assessed by FISH utilizing dual-
color, break-apart probes (from Vysis/Abott, Baar, Switzerland), while the FOXP1 gene status 
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was determined by bacterial artificial chromosome clones RP11-118O11, RP11-1031N18, 
RP11-430J3 and RP11-154H23, RP11-321A23, RP11-266022 flanking the FOXP1 locus, 
both as described.21,22 Slides were counterstained with 125 ng/ml 4’,6-diamino-2-
phenylindole in antifade solution. FISH signals were scored with a Zeiss fluorescence 
microscope equipped with double-band pass filters for simultaneous visualization of 
Spectrum Green and Spectrum Orange signals. Cases on the TMA were considered evaluable 
for FISH if at least 200 tumor cell nuclei per core displayed positive signals. Splits were 
recorded as percentage of cells bearing an abnormality out of all analyzed cells. The cut-off 
score to consider a case rearranged was the mean plus three standard deviations of split nuclei 
in reactive lymph nodes and tonsils (i.e. 4% for MYC and 3% for FOXP1). The minimal 
distance of split signals was defined as at least three single signal widths.  
 
Cell lines, transfections and luciferase reporter assays 
On-target plus smartpool siRNAs for MYC, FOXP1 and a scrambled negative control was 
purchased from Dharmacon (Thermo Scientific, Lafayette, CO, USA). Precursor microRNA 
oligonucleotides (pre-miR-let-7a, pre-miR-34a, pre-miR-23a, pre-miR-26a, pre-miR-150 and 
pre-miR-15) and scrambled negative control oligonucleotides were purchased from Ambion. 
For the purpose of siRNA or miRNA introduction into DLBCL cells, 1x106 cells were 
nucleoporated using an Amaxa Nucleoporator (Gaithersburg, MD, USA) with the specified 
amount of pre-miR miRNA precursor or siRNA. After 48 h, cells were harvested for RNA 
and protein analysis. After 72 h, tumor cell proliferation was quantified by [3H]-thymidine 
incorporation assay as previously described.5 The pmirGLO Dual-Luciferase miRNA Target 
Expression Vector was purchased from Promega (Madison, WI, USA). HEK293T cells were 
seeded into 21-well plates at 1 x 105 cells/well 24 h before transfection. 1 μg reporter plasmid 
containing the FOXP1 3’UTR or its mutants and 30nM mir-34a precursor molecules were co-
transfected into each well using the Fugene 6 transfection reagent (Roche) in triplicates. 
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Luciferase assays were performed 24 hr after transfection using the Dual-Luciferase Reporter 
Assay System (Promega) with a Spectramax M5 reader (Molecular Devices, CA, USA). 
 
DNA methylation analysis of the miR-34a promoter 
Specific oligonucleotides for methylation specific PCR of the miR-34a CpG island were 
described previously.23 Genomic DNA was isolated from FFPE tissue and fresh material 
using the RecoverAll total RNA Isolation kit (Ambion, Streetsville, Canada) and the DNeasy 
Blood and Tissue Kit (Qiagen, Valencia, CA), respectively. 2 µg gDNA was converted with 
sodium bisulfite as previously reported.24 Following amplification of the bisulfite-converted 
DNA, the methylation status was assessed by PCR as described previously.23 PCR products 
were separated by electrophoresis on polyacrylamide gels and visualized under ultraviolet 
light after staining with ethidium bromide.  
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RESULTS  
 
Myc-repressed miRNAs are specifically downregulated in high grade-transformed 
gastric lymphoma  
To obtain global miRNA expression signatures of gDLBCL and its precursor lesions, total 
RNA isolated from 7-8 cases each of Helicobacter-associated gastritis, low grade MALT 
lymphoma and gDLBCL was hybridized to Agilent miRNA microarrays representing 795 
human mature miRNAs. Unsupervised hierarchical clustering analysis revealed a clear 
segregation of the gDLBCL cases from the low grade MALT lymphomas and the gastritis 
samples (Figure 1A). The segregation of the latter two disease entities was incomplete (Figure 
1A), reflecting the relative biological similarity of gastritis and low grade lymphomas. 
Statistical analysis of the dataset revealed only 25 differentially expressed miRNAs between 
these two groups (p<0.05; suppl. Table 1), whereas 88 miRNAs exhibited significant 
differences in expression between low and high grade lymphomas (suppl. Table 2).  
In order to identify miRNAs with a putative tumor suppressive role in high grade 
transformation, we focused on the subset of 57 miRNAs that were downregulated in high 
grade, but not in low grade tumors (suppl. Table 2). Interestingly, a large fraction of the 
downregulated miRNAs had previously been reported to be repressed by the Myc 
transcription factor through a mechanism involving the direct association of Myc with pri-
miRNA promoters.25 In fact, we found that of the 30 known human Myc-repressed miRNAs, 
27 were downregulated by at least 1.8- and up to 8.7 fold in high grade vs. low grade gastric 
lymphomas (annotated in Figure 1A). The differential expression of two selected miRNAs, 
let-7a and miR-34a, was verified on the same panel of samples by locked nucleic acid (LNA) 
real time RT-PCR (Figure 1B,C). To obtain more direct evidence that miRNA dysregulation 
is involved in high grade transformation of gastric lymphoma, we examined let-7a and miR-
34a expression in paired samples of three gastric lymphoma patients for which both low and 
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high grade tumor material was available. In all cases, expression of the miRNAs was 
significantly lower in the high grade compared to the low grade component of the tumor 
(Figure 1D,E). In conclusion, we found using genome-wide miRNA expression profiling that 
high grade transformation of gastric MALT lymphoma is accompanied by a characteristic 
signature of repressed miRNAs, a substantial number of which are encoded by known target 
genes of Myc. 
 
A highly similar signature of Myc-repressed genes distinguishes aggressive from 
indolent nodal and gastric lymphomas 
To determine whether our signature of differentially expressed miRNA genes was specific to 
gastric lymphoma, we compared it to an independently conducted study analyzing miRNA 
expression in nodal lymphomas. To this end, our lists of differentially expressed miRNA 
genes were compared to miRNAs that differed in expression between four follicular 
lymphomas and four nodal DLBCL cases as assessed by 454 deep sequencing. Surprisingly, a 
highly significant overlap existed among the down-regulated miRNAs; specifically, 42 out of 
the 57 miRNAs down-regulated in gDLBCL, but not gastric MALT lymphoma, were also 
down-regulated in nodal DLBCL (p<0.001; Figure 2). This overlap was particularly 
compelling as different technology platforms (microarray-based expression profiling vs. deep 
sequencing) had been used. Down-regulation of almost the entire set of known Myc-repressed 
miRNAs was a shared feature of gastric and nodal DLBCL (marked in red; Figure 2). In 
conclusion, the result indicates that the transformation from indolent to aggressive lymphoma 
is accompanied by the suppression of similar sets of miRNA genes in the nodal and 
extranodal disease counterparts, and implies that similar patho-mechanisms are operative in 
both disease entities. 
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Myc is over-expressed in gastric DLBCL and controls DLBCL proliferation in vitro  
Having obtained indirect evidence of Myc overexpression in gDLBCL, but not in low grade 
MALT lymphoma, we next aimed to assess the Myc expression status of a set of 37 gDLBCL 
and 39 low grade lymphomas spotted onto a gastric lymphoma tissue microarray.20 Indeed, 
80% of gDLBCL, but only 20% of low grade lymphomas showed high expression of Myc 
(Figure 3A,B) despite the fact that none of the cases harbored chromosomal translocations 
involving the MYC genomic locus as determined by FISH analysis (suppl. Table 3). This 
differential expression of Myc in low and high grade gastric lymphoma was further 
substantiated in the three patients for which tissue was available for both the low grade and 
high grade tumor component (Figure 3C,D). Myc expression also differed strongly in the 
gastric lymphoma cases used for the microRNA expression profiling shown in Figure 1; most 
of the gDLBCL cases, but none of the MALT lymphomas, expressed moderate or high levels 
of Myc (suppl. Table 4). To assess a possible causal link between Myc expression and 
miRNA downregulation in DLBCL, we transiently knocked down Myc expression in two 
DLBCL lines, of which one has the characteristics of the ‘activated B-cell’ type of DLBCL 
(‘ABC’; U2932) and the other has typical ‘germinal center B-cell’ features (‘GCB’, 
SUDHL4). Neither cell line harbors chromosomal rearrangements involving the MYC 
genomic locus. The transient knock-down of Myc indeed increased expression of both let-7a 
(Figure 3E) and miR-34a (Figure 3F) in both cell lines in relation to a scrambled siRNA. 
Interestingly, the proliferation of both DLBCL cell lines as determined by [3H] thymidine 
incorporation was significantly reduced upon siRNA-mediated Myc knock down (Figure 
3G,H). In contrast, the proliferation of a low grade marginal zone lymphoma (MZL) cell line, 
SSK41, was not reduced upon knock down of Myc (suppl. Figure 1). The combined results 
suggest that Myc expression drives the proliferation of transformed, but not indolent 
lymphomas, possibly via downregulation of tumor suppressive miRNAs.  
To determine which of the Myc-repressed miRNAs have tumor suppressive properties in . 
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DLBCL cell lines in vitro, we focused on a panel of six miRNAs that were consistently 
predicted by both the TargetScan and PicTar algorithms to target known or putative 
hematopoietic oncogenes such as Bcl6, Pim1, FoxP1 and Pax5. We introduced synthetic, 
chemically modified double-stranded precursor molecules of the six miRNAs (so-called pre-
miRs™) into U2932 and SUDHL4 cells by electroporation, either alone or in combination 
(Figure 3I,J). While all Myc-suppressed miRNAs on our panel had suppressive effects on 
tumor cell proliferation in relation to a scrambled negative control miRNA (Figure 3I,J) and 
an irrelevant miRNA not regulated by Myc (suppl. Figure 2), one candidate, miR-34a, was 
particularly effective in this respect. miR-34a is a known tumor suppressor miRNA in prostate 
and lung cancer and is a lead candidate for miRNA replacement therapy for the treatment of 
these malignancies.26  
As miR-34a is known to be repressed by Myc,25 and to be transcriptionally activated by p53,27 
we examined the p53 mutation status of the MALT lymphoma and gDLBCL cases included 
in our tissue microarray. Only 3 of the 37 included cases of gDLBCL and 5 of the 39 MALT 
lymphoma cases exhibited evidence of mutated p53, i.e. they expressed high levels of p53, 
but low levels of its target gene p21 (suppl. Table 3). Myc expression was not correlated 
(directly or inversely) with p53 mutation status; both observations combined indicate that the 
p53 status is not a useful marker in gastric lymphomagenesis and argue against an important 
role of p53 inactivation in high grade transformation.  
The mechanism of gene repression by Myc remains poorly understood; one line of evidence 
suggests that Myc recruits the DNA CpG methyltransferase Dnmt3a to the promoters of its 
negatively regulated target genes, an example of which is p21.28 To investigate whether miR-
34a promoter methylation may contribute to its dysregulation in gDLBCL, we performed 
methylation-specific PCR analyses of a CpG island that surrounds the transcriptional start site 
of the miR-34a pri-miRNA. The island is located >30kb upstream of the position of mature 
miR-34a and has been reported to be relevant for its regulation.29 We compared the 
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methylation status of multiple cases each of gastric low and high grade lymphoma and of the 
low and high grade disease components of the three paired cases shown in Figure 1D and E. 
Interestingly, none of the seven low grade MALT lymphomas, but four of the seven gDLBCL 
samples analyzed exhibited miR-34a promoter hypermethylation (Figure 3K,L), indicating 
that epigenetic silencing (Myc-dependently or -independently) may contribute to miR-34a 
dysregulation in gDLBCL. In particular, two of the three paired samples exhibited miR-34a 
promoter methylation in the high grade, but not the low grade tumor component (Figure 3L). 
Interestingly, we further found using the Progenetix oncogenomic database 
(www.progenetix.net)30 that approximately 10% of the 1096 DLBCL cases for which CGH 
data is available show loss of the region on chromosome 1 that contains the miR-34a locus 
(suppl. Figure 3). In conclusion, we show here that miR-34a has tumor suppressive activity in 
DLBCL cell lines, and that its expression is regulated by Myc and/or through mechanisms 
that may involve epigenetic silencing of the miR-34a promoter or chromosomal deletion of 
the miR-34a genomic locus.  
 
miR-34a targets the transcription factor FoxP1 in DLBCL 
Bioinformatically predicted targets of miR-34a include the transcription factors Bcl6 and 
FoxP1, which harbor one and two putative miR-34a seed regions in their 3’ untranslated 
region (UTR), respectively. As both have previously been linked to the pathogenesis of 
gDLBCL,8,31 we aimed to test their possible post-transcriptional regulation by miR-34a in the 
DLBCL cell lines introduced earlier. Quantitative RT-PCR of FoxP1 and Bcl6 expression 
after electroporation of U2932 and SUDHL4 cells with pre-miR-34a revealed that FoxP1, but 
not Bcl6, is a likely direct target of this miRNA (Figure 4A and data not shown). Protein 
levels of FoxP1 were also strongly reduced upon introduction of miR-34a into U2932 cells 
(Figure 4B). In order to measure a direct effect of miR-34a binding to its seed regions in the 
FOXP1 gene, we cloned the wild type sequence of the seed region, or a mutant version in 
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which four of the six positions had been mutated, downstream of a luciferase reporter gene. 
Co-transfection of pre-miR-34a with the luciferase expression vector harboring the wild type 
seed region, but not the mutant version, blocked reporter gene expression as assessed by 
luciferase activity assay (Figure 4C). Interestingly, siRNA-mediated knock-down of Myc was 
as efficient as pre-miR-34a introduction in inhibiting FoxP1 expression (suppl. Figure 4). In 
summary, our results demonstrate that FoxP1 is a target of miR-34a and (an indirect target) of 
Myc in DLBCL cell lines. As Myc has been shown in a previous report to itself be targeted by 
miR-34a,32 we examined a possible reciprocal interaction of both factors in the context of 
DLBCL cells. We were indeed able to confirm that Myc expression is negatively regulated by 
miR-34a (suppl. Figure 5), implying that the loss of miR-34a expression in gDLBCL may 
further de-repress Myc and perpetuate the oncogenic consequences of Myc dysregulation. 
 
The miR-34a target FoxP1 is a bona fide oncoprotein in DLBCL 
As FoxP1 is a direct target of miR-34a, we asked whether FoxP1 is differentially expressed in 
gDLBCL and low grade MALT lymphoma. Indeed, a majority of gDLBCL, but very few of 
the low grade lymphoma cases spotted onto our tissue microarray showed reactivity with a 
FoxP1-specific antibody (Figure 5A,B). Interestingly, all FoxP1-positive cases also expressed 
Myc, irrespective of whether they were classified as low grade or high grade lymphomas 
(suppl. Table 3). On the other hand, FoxP1 expression was not significantly correlated with 
expression of Bcl6, which is often used to distinguish between ‘GCC’ and ‘ABC’ type 
DLBCL: similar proportions of FoxP1-positive cases were Bcl6-positive and –negative 
(suppl. Table 3). Chromosomal rearrangements involving the FOXP1 genomic locus were not 
detected by FISH in any of the MALT lymphoma or gDLBCL cases spotted onto our tissue 
microarray (suppl. Table 3), ruling out that FoxP1 dysregulation is caused by genomic events. 
Interestingly, the differential expression of FoxP1 in gastric low and high grade lymphoma 
could be confirmed on the three pairs of low grade and high grade tumor components 
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harvested from the same patients (Figure 5C,D). FoxP1 expression analysis of the gastric 
lymphoma cases used for microRNA expression profiling also showed higher FoxP1 
expression in the high grade than in the low grade cases (suppl. Table 4). Having shown that 
FoxP1 is overexpressed in gDLBCL, we postulated that the siRNA-mediated knock down of 
FoxP1 should have similar anti-proliferative effects in DLBCL cell lines as the delivery of 
miR-34a. This was indeed the case: knock down of FoxP1 by ~64% (suppl. Figure 6) blocked 
the proliferation of four ‘GCB’ and ‘ABC’ type DLBCL cell lines at similar levels, and 
roughly as efficiently as the re-introduction of miR-34a (Figure 5E-H). In contrast, the 
proliferation of SSK41 low grade MZL cells was not reduced upon knock down of FoxP1, 
and was only modestly reduced by miR-34a (suppl. Figure 7). In conclusion, our results 
suggest that the transcription factor FoxP1 is a direct target (yet probably not the only target) 
of miR-34a that is overexpressed in gDLBCL, but not in low grade lymphoma, and represents 
a bona fide oncoprotein in DLBCL. Taken together, our results establish a mechanistic link 
between over-expression of Myc, the concomitant repression of Myc-regulated miRNA 
genes, and the deregulation of FoxP1 (see schematic in Figure 6).    
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DISCUSSION 
Gastric DLBCL is an aggressive fast-growing disease with inferior survival rates compared to 
MALT lymphoma. The potential contribution of miRNA deregulation to high grade 
transformation of MALT lymphoma is unknown. Here, we used a genome-wide microarray 
approach to compare the miRNA expression profiles of gastric MALT lymphoma and 
gDLBCL. Of the substantial number of miRNAs differentially expressed between the two 
disease entities, a large majority were downregulated in the gDLBCL cases analyzed. Global 
reduction of miRNA expression is a hallmark of cancer progression and is thought to 
contribute to neoplastic transformation by allowing increased expression of oncoproteins.33 
The Myc oncoprotein is known to directly suppress the expression of a large number of 
human miRNAs, thereby contributing to the phenomenon of reduced abundance of miRNAs 
in cancer cells.25,34,35 A Myc-repressed miRNA signature was found to characterize both 
gastric and nodal DLBCL; Myc over-expression was much more common in gDLBCL than in 
low grade MALT lymphoma. Chromosomal aberrations involving the MYC locus are reported 
in the literature for a subset of gDLBCL, but are never detected in gastric low grade 
lymphomas and rarely found in nodal DLBCL.22,36,37 We did not detect chromosomal 
translocations involving MYC in any of our 37 gDLBCL cases analyzed. Myc is itself known 
to be post-transcriptionally regulated by miRNAs.32 Interestingly, several Myc-regulating 
miRNAs (including miR-34a and let7a) are also targets of Myc repression,32 establishing a 
feedback loop that aggravates and perpetuates the effects of Myc overexpression and may 
thus contribute to cancer progression. 
Several lines of evidence argue that the Myc-regulated miRNA miR-34a acts as a strong 
tumor suppressor in solid cancers. It is located on chromosome 1p36.22 in a region that has 
previously been associated with various malignancies, including lung cancer;17 it is 
transcriptionally induced by the tumor suppressor p53 and its overexpression inhibits growth 
of various cancer types in vitro.27 The first proof of principle for the success of miR-34a 
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“replacement therapy” in cancer treatment was recently reported using a preclinical model of 
non-small cell lung cancer; the local and systemic delivery of chemically synthesized miR-
34a was achieved in this model by formulation with a lipid-based delivery reagent.26 We 
demonstrate here for the first time that miR-34a has tumor suppressive properties in DLBCL. 
It is downregulated in the highly malignant compared to the indolent form of gastric and 
nodal lymphoma and its expression is directly regulated by Myc, which we show here to 
possess oncogenic properties in various DLBCL, but not low grade lymphoma cell lines. 
Ectopic miR-34a re-expression strongly inhibits DLBCL proliferation; in line with another 
recent report, we demonstrate here that miR-34a directly targets a suspected hematopoietic 
oncogene, FOXP1, by binding to at least one of two predicted seed regions in the FOXP1 
3’UTR.38 In addition, we found that FoxP1 is over-expressed in the high grade form of gastric 
lymphoma and indeed possesses bona fide oncogenic properties in DLBCL cell lines, 
suggesting that it represents a relevant, but probably not an exclusive, target of miR-34a in 
this disease entity. 
Recent attention has focused on FoxP1 and its potential role in tumorigenesis due to its 
upregulation in a variety of B-cell neoplasias. Our results confirm and extend previous reports 
linking FoxP1 overexpression to poor prognosis in MALT lymphoma and DLBCL.21,39 The 
post-transcriptional regulation of FoxP1 by miR-34a further provides a plausible explanation 
for the conundrum that FoxP1 is highly expressed in many lymphomas not harboring the rare 
chromosomal translocation t(3;14)(p13;q32), which juxtaposes the FOXP1 and IGH gene loci 
in certain non-gastric MALT lymphomas and extranodal DLBCL.40,41 In conclusion, we 
propose here that miR-34a replacement therapy should be considered not only for the 
treatment of solid cancers, but may also be beneficial in patients with miR-34a-negative, 
FoxP1-overexpressing hematopoietic malignancies such as gastric DLBCL. The beneficial 
therapeutic effects of miR-34a are anticipated due to the strong tumor suppressive properties 
of this miRNA, which are exerted via regulation of its oncogene target FoxP1.   
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FIGURE LEGENDS 
Figure 1. A Myc-repressed miRNA signature distinguishes gastric DLBCL from low 
grade MALT lymphoma. (A) The expression of 795 human mature miRNAs included in 
version 10.0 of the miRBase database was analyzed for seven cases of gastritis, eight cases of 
low grade MALT lymphoma (MALT-L) and seven gDLBCL cases using microarray 
technology. The result of unsupervised hierarchical clustering of all miRNAs that varied 
across the 22 arrays with a standard deviation of log2 expression >0.05 is shown in the heat 
diagram. All known Myc-repressed miRNAs with lower expression in gDLBCL compared to 
low grade MALT-L are annotated along with their fold change in expression (averaged across 
groups) between gDLBCL and MALT-L (in brackets). (B,C) Quantification of let-7a (B) and 
miR-34a (C) expression in the samples shown in A by LNA real-time RT-PCR; absolute 
expression was normalized to U6 snRNA. p-values were calculated by unpaired t-test. (D,E) 
Quantification of let-7a (D) and miR-34a (E) expression in matched MALT-L and gDLBCL 
samples from three patients with gastric lymphoma.  
 
Figure 2. Venn diagram of unique and shared miRNAs downregulated in gastric and/or 
nodal DLBCL. The miRNAs differentially down-regulated in high compared to low grade 
gastric lymphoma (as assessed by microarray analysis, Figure 1), were compared to the 
miRNAs differentially down-regulated in aggressive compared to indolent nodal lymphoma 
(as assessed by 454 deep sequencing). A total of 745 miRNAs were detected in the 
microarray/gastric lymphoma study; 57 of these were significantly down-regulated in gastric 
DLBCL by more than 1.5 fold compared to MALT lymphoma. 298 miRNAs were detected in 
the deep-sequencing/nodal lymphoma study, of which 87 were downregulated by more than 
1.8 fold in the aggressive nodal lymphomas compared to their indolent counterparts.  42 
down-regulated miRNAs (*p<0.001 as assessed by Fisher’s exact test) were found to be 
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shared between gastric and nodal DLBCL cases compared to the respective indolent disease 
counterparts. miRNAs known to be repressed by Myc are highlighted in red.   
 
Figure 3. Myc is over-expressed in gDLBCL and exhibits oncogenic properties in 
DLBCL cell lines in vitro. (A,B) Myc expression was analyzed by immunohistochemistry on 
a tissue microarray comprising 37 gDLBCL and 39 low grade MALT lymphoma (MALT-L) 
cases. Representative micrographs are shown in A; the fraction of MALT lymphoma and 
gDLBCL cases with high, low and no Myc expression is indicated in B. (C,D) Myc 
expression as analyzed by immunohistochemistry of matched low grade and high grade 
lymphoma material from three patients. Representative micrographs are shown for case 1 in 
C; scores on a scale of 0-3 are shown for all cases in D. The scale bar indicates 50μm. (E,F) 
Quantification of let-7a (E) and miR-34a (F) expression as determined by LNA real-time RT-
PCR for the indicated cells lines (U2932, SUDHL4) 48h after electroporation with Myc-
specific or scrambled (NC) siRNA. Expression values were normalized to U6 snRNA levels. 
(G,H) Proliferation as assessed by [3H] thymidine incorporation of U2932 (G) and SUDHL-4 
(H) cells 72 h after electroporation with Myc-specific or scrambled (NC) siRNA. (I,J) 
Proliferation as assessed by [3H] thymidine incorporation of U2932 (I) and SUDHL-4 (J) cells 
72 h after electroporation with the indicated pre-miRs or scrambled negative control (NC) 
oligonucleotide. (K,L) miR-34a promoter methylation as determined by methylation-specific 
PCR of four unrelated cases each of MALT lymphoma (K, upper panel) and gDLBCL (K, 
lower panel) as well as three matched low and high grade lymphoma samples from the same 
patients (cases 1-3, L). U denotes “unmethylated”, M denotes “methylated”. The Myc staining 
in A and B was performed twice with similar results; the experiments shown in E-J were each 
reproduced 3 to 4 times. 
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Figure 4. miR-34a directly targets FoxP1 in DLBCL. (A) U2932 cells were electroporated 
with pre-miR34a or a scrambled negative control pre-miR and analyzed with respect to FoxP1 
expression 48 h later. FoxP1 transcript levels were normalized to GAPDH expression. (B) 
FoxP1 protein levels of the experiment described in A as analyzed by Western blot. α-tubulin 
levels are shown to control for equal loading. (C) Dual luciferase assay of HEK293T cells co-
transfected with firefly luciferase constructs containing the wild-type or mutant miR-34a 
target site of the FOXP1 3'UTR region downstream of the luciferase reporter. Cells were co-
transfected with either pre-miR-34a or a negative control scrambled oligonucleotide and the 
respective luciferase construct. Data are represented as relative luciferase activity. All 
experiments were reproduced at least 3 times. 
 
Figure 5. FOXP1 is a bone fide oncoprotein in DLBCL. (A,B) FoxP1 expression was 
analyzed by immunohistochemistry using the tissue microarray described in Figure 3. 
Representative micrographs are shown in A; the fraction of MALT lymphoma and gDLBCL 
cases with high, low and no FoxP1 expression is shown in B. The scale bar indicates 50μm. 
(C,D) FoxP1 expression as analyzed by immunohistochemistry of matched low grade and 
high grade lymphoma material from the same patients. Representative micrographs are shown 
for case 1 in C; scores on a scale of 0-3 are shown for all three cases in D. (E-H) Proliferation 
as determined by [3H] thymidine incorporation of U2932 (E), SUDHL4 (F), SUDHL6 (G) and 
SUDHL7 (H) cells 72 h prior after electroporation with pre-miR34a, a FoxP1-specific siRNA 
or the respective negative control (NC) scrambled oligonucleotides. The FoxP1 staining in A-
D was performed twice with similar results; the experiments shown in E-H were reproduced 
at least 3 and up to 5 times. 
  
Figure 6. Schematic representation of the interplay between Myc, miR-34a and FoxP1 
during malignant transformation of low grade gastric MALT lymphoma to gDLBCL. 
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Myc overexpression can be caused by chromosomal translocations involving MYC and IG 
loci or other genetic abnormalities, or by post-transcriptional regulation through miRNAs 
such as members of the let7 family and miR-34a (as first shown by Christoffersen et al.32). 
Antigen dependence is lost during malignant transformation.  
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